Evidence map›Paper›PMID 36561961›Full record

ReviewToxicology reports2022

Ampelopsin targets in cellular processes of cancer: Recent trends and advances.

Hardeep Singh Tuli, Katrin Sak, Vivek Kumar Garg, Ajay Kumar, Shubham Adhikary, Ginpreet Kaur, Nidarshana Chaturvedi Parashar, Gaurav Parashar, Tapan Kumar Mukherjee, Uttam Sharma and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Toxicology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 1 country.

Hardeep Singh TuliDepartment of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana 133207, India.
Katrin SakNGO Praeventio, Tartu 50407, Estonia.
Vivek Kumar GargDepartment of Medical Laboratory Technology, University Institute of Applied Health Sciences, Chandigarh University, Gharuan, Mohali 140413, Punjab, India.
Ajay KumarDepartment of Botanical and Environmental Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India.
Shubham AdhikaryShobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai 40056, Maharashtra, India.
Ginpreet KaurShobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, Mumbai 40056, Maharashtra, India.
Nidarshana Chaturvedi ParasharDepartment of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana 133207, India.
Gaurav ParasharDepartment of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana 133207, India.
Tapan Kumar MukherjeeDepartment of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana 133207, India.
Uttam SharmaDepartment of Zoology, Central University of Punjab, Village-Ghudda, 151401 Punjab, India.
Aklank JainDepartment of Zoology, Central University of Punjab, Village-Ghudda, 151401 Punjab, India.
Ranjan K MohapatraDepartment of Chemistry, Government College of Engineering, Keonjhar 758002, Odisha, India.
Kuldeep DhamaDivision of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh 243122, India.
Manoj KumarDepartment of Chemistry, Maharishi Markandeshwar University, Sadopur-Ambala 134007, Haryana, India.
Tejveer SinghSchool of life Science, Jawaharlal Nehru University, New Delhi, India.
Maharishi Markandeshwar University, Mullana · INCentral University of Punjab · INNarsee Monjee Institute of Management Studies · INChandigarh University · INGovernment College of Engineering, KeonjharGuru Nanak Dev University · INIndian Veterinary Research Institute · INJawaharlal Nehru University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is being considered as a serious threat to human health globally due to limited availability and efficacy of therapeutics. In addition, existing chemotherapeutic drugs possess a diverse range of toxic side effects. Therefore, more research is welcomed to investigate the chemo-preventive action of plant-based metabolites. Ampelopsin (dihydromyricetin) is one among the biologically active plant-based chemicals with promising anti-cancer actions. It modulates the expression of various cellular molecules that are involved in cancer progressions. For instance, ampelopsin enhances the expression of apoptosis inducing proteins. It regulates the expression of angiogenic and metastatic proteins to inhibit tumor growth. Expression of inflammatory markers has also been found to be suppressed by ampelopsin in cancer cells. The present review article describes various anti-tumor cellular targets of ampelopsin at a single podium which will help the researchers to understand mechanistic insight of this phytochemical.

Indexed as

AmpelopsinAngiogenesis inhibitionAnti-inflammationAnti-proliferationApoptoticCell cycle arrest

Identifiers

PMID36561961
PMCPMC9764188
OpenAlexW4288056655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.